Article
Single-cell repertoire tracing identifies rituximab refractory B cells during myasthenia gravis relapses
2019-11-14
Abstract excerpt
Rituximab, a B cell-depleting therapy, is indicated for treating a growing number of autoantibody-mediated autoimmune disorders. However, relapses can occur after treatment and autoantibody-producing B cell subsets may be found during relapses. It is not understood if these autoantibody-producing B cell subsets emerge from the failed depletion of pre-existing B cells or are re-generated de novo . To further defin...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 67f0983d-278c-5e0b-a227-a432ed0937ee
- DOI
- 10.1101/840389
